Federal Circuit Invalidates Gene Therapy Patents in Favor of Pfizer, Reshaping Biotech Landscape

The United States Court of Appeals for the Federal Circuit has supported the findings of the Patent Trial and Appeal Board, ruling that a pair of patents concerning an innovative gene therapy for hemophilia are invalid. This decision marks a notable victory for Pfizer, the company challenging these patents. This ruling potentially destabilizes the position of the patent holder, asserting Pfizer’s stance in the highly competitive field of gene therapy innovations. The considerations surrounding such legal decisions are crucial for stakeholders involved in biotechnology patent disputes, as they influence both strategic legal planning and future biotechnology research endeavors. For further details on the case specifics and implications, visit the full article on Law360.